Tillkännagivande • Apr 01
BioNexus Gene Lab Corp. announced delayed annual 10-K filing On 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Mar 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Dec 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap). Reported Earnings • Nov 17
Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024) Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024). Tillkännagivande • Nov 17
BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025 BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025. Tillkännagivande • Nov 08
BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Tillkännagivande • Aug 15
BioNexus Gene Lab Corp. announced delayed 10-Q filing On 08/14/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Jun 26
Bionexus Gene Lab Corp. Announces CFO Changes, Effective June 17, 2025 On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight. Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company. Tillkännagivande • Apr 01
BioNexus Gene Lab Corp. announced delayed annual 10-K filing On 03/31/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Board Change • Feb 14
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 03
Hearing Panel of Nasdaq Grants Temporary Exception to BioNexus Gene Lab to Regain Compliance with Bid Price Rule On December 27, 2024, BioNexus Gene Lab Corp. received a written notice from the Nasdaq Hearings Panel indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May 1, 2025, will result in the delisting of the Company’s common stock from The Nasdaq Capital Market. Additionally, Nasdaq has updated its rules regarding reverse stock splits. Effective January 30, 2025, the Company must notify Nasdaq of specific details, including the date of shareholder approval, at least ten (10) calendar days prior to the anticipated market effective date of the reverse stock split. The Company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe and will provide updates as appropriate. Tillkännagivande • Nov 15
BioNexus Gene Lab Corp. announced delayed 10-Q filing On 11/14/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Nov 09
BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination On November 5, 2024, BioNexus Gene Lab Corp. (the "Company") received a notification from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from the Nasdaq Capital Market due to its failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. The Company had been provided two consecutive 180-day grace periods, ending on November 4, 2024, to regain compliance but was unable to meet the requirement within the designated period. In response, on November 8, 2024, the Company submitted a formal request for a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The Nasdaq Hearings Department has acknowledged receipt of the Company's hearing request, which stays the suspension of trading of the Company's common stock pending a decision by the Panel. The Company intends to present a compliance plan at the hearing, including potential corrective actions such as a reverse stock split, among other strategic initiatives, to regain compliance with Nasdaq's listing standards. Tillkännagivande • Oct 18
Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of BioNexus Gene Lab Corp., effective immediately. Mr. Wong was also a Member of the Audit Committee, and a Member of the Corporate Governance and Nominating Committee. Tillkännagivande • Sep 10
BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024 BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024. Reported Earnings • Aug 16
Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023) Second quarter 2024 results: US$0.005 loss per share (improved from US$0.018 loss in 2Q 2023). Revenue: US$11.9k (down 100% from 2Q 2023). Net loss: US$93.4k (loss narrowed 64% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Board Change • Jun 28
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • May 10
The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until May 6, 2024, to regain compliance. The Company requested in writing an additional 180-calendar day compliance period after the expiration of the Initial Period to regain compliance with the Nasdaq requirements and informed Nasdaq of its intention to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary. On May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the ‘Additional Period’), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional Period, the Staff will provide written notice that the Common Stock will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the ‘Panel’), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria. Tillkännagivande • Mar 29
BioNexus Gene Lab Corp. announced delayed annual 10-K filing On 03/28/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Board Change • Feb 14
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Jan 17
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp On January 17, 2024, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong announced that on December 11, 2023, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong executed a Written Consent to Action Without Meeting of the Shareholders (the Written Consent) removing the certain Board members and appointing three new board members of the shareholders’ choosing. Tillkännagivande • Nov 15
BioNexus Gene Lab Corp. announced delayed 10-Q filing On 11/14/2023, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Nov 14
BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in particular, the period September 20, 2023 through November 3, 2023), the Company failed to meet the aforesaid requirement. Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until May 6, 2024, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by Nasdaq. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria. Board Change • Nov 14
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Sep 09
BioNexus Gene Lab Corp. Announces Executive Changes BioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023. Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group’s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services. New Risk • Aug 17
New major risk - Revenue and earnings growth Earnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$11.5m market cap). Reported Earnings • Aug 17
Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022) Second quarter 2023 results: US$0.001 loss per share. Revenue: US$2.57m (up 3.3% from 2Q 2022). Net loss: US$259.3k (loss widened 87% from 2Q 2022). New Risk • Jul 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (70% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$55.7m market cap). Board Change • Jul 21
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. COO & Executive Director Liong Tan is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Feb 16
BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.
Security Name: Common Stock
Security Type: Common Stock Tillkännagivande • Apr 03
BioNexus Gene Lab Corporation announced delayed annual 10-K filing On 04/01/2022, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • May 18
BioNexus Gene Lab Corporation announced delayed 10-Q filing On 05/17/2021, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Jan 01
BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. on December 24, 2020. Under terms, BioNexus Gene Lab Corporation will issue 68.48 million shares. As of December 31, 2019 Chemrex generated a revenue of $15.6 million and net income of $.30 million. Post acquisition Chemrex will become wholly-owned subsidiary of BioNexus. The transaction is subject to regulatory approvals. The transaction is expected to close on December 31, 2020. 